Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
In: Clinical Infectious Diseases, Jg. 72 (2021-01-15), Heft 2, S. 202-211
academicJournal
Zugriff:
Background Hepatitis B virus RNA (HBV-RNA) is a novel serum biomarker that correlates with transcription of intrahepatic covalently closed circular (cccDNA), which is an important target for pegylated interferon (PEG-IFN) and novel therapies for functional cure. We studied HBV-RNA kinetics following PEG-IFN treatment and its potential role as a predictor to response in HBeAg-negative chronic hepatitis B (CHB) patients. Methods HBV-RNA levels were measured in 133 HBeAg-negative CHB patients treated in an international randomized controlled trial (PARC study). Patients received PEG-IFN α-2a for 48 weeks. HBV-RNA was measured from baseline through week 144. Response was defined as HBV-DNA <2000 IU/mL and ALT normalization at week 72. Kinetics of HBV-RNA were compared with HBV-DNA, HBsAg, and HBcrAg. Results Mean HBV-RNA at baseline was 4.4 (standard deviation [SD] 1.2) log 10 c/mL. At week 12, HBV-RNA declined by −1.6 (1.1) log 10 c/mL. HBV-RNA showed a greater decline in responders compared to nonresponders early at week 12 (−2.0 [1.2] vs −1.5 [1.1] log 10 c/mL, P = .04). HBV-RNA level above 1700 c/mL (3.2 log 10 c/mL) had a negative predictive value of 91% at week 12 and 93% at week 24 (P = .01) for response. Overall, HBV-RNA showed a stronger correlation with HBV-DNA and HBcrAg (.82 and.80, P < .001) and a weak correlation with HBsAg (.25). At week 12, HBV-RNA was significantly lower among patients with lower HBsAg (<100 IU/mL) or HBsAg loss at week 144. Conclusions During PEG-IFN treatment for HBeAg-negative CHB, HBV-RNA showed a fast and significant decline that correlates with treatment response and HBsAg loss at long-term follow-up. Clinical Trials Registration NCT00114361 [ABSTRACT FROM AUTHOR]
Copyright of Clinical Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
|
---|---|
Autor/in / Beteiligte Person: | Farag, Mina S ; Campenhout, Margo J H van ; Pfefferkorn, Maria ; Fischer, Janett ; Deichsel, Danilo ; Boonstra, André ; Vuuren, Anneke J van ; Ferenci, Peter ; Feld, Jordan J ; Berg, Thomas ; Hansen, Bettina E ; Bömmel, Florian van ; Janssen, Harry L A |
Zeitschrift: | Clinical Infectious Diseases, Jg. 72 (2021-01-15), Heft 2, S. 202-211 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 1058-4838 (print) |
DOI: | 10.1093/cid/ciaa013 |
Schlagwort: |
|
Sonstiges: |
|